SCIENTIFIC INDUSTRIES INC (SCND) Form 10-Q — Aug 13, 2026
Scientific Industries reported Q2 fiscal 2026 revenue of $1,470,400, up 36.0% from $1,081,000 a year earlier, and cut its net loss to $1,233,800 ($0.10 per share) from $1,523,700 ($0.13). Six-month revenue rose 33.3% to $2,697,500 while the six-month net loss narrowed to $2,823,100 from $3,302,200. Results reflect a slimmer company after the August 2025 sale of the Genie Division to Troemner for $9,600,000 plus an earn-out of up to $1,500,000. Gross margin improved to 42.3% from 34.8% on higher-margin Torbal and VIVID products and the DOTS bioprocessing line, though the Bioprocessing Systems segment still lost $1,071,000 in the quarter on just $274,200 of revenue.
Key figures
- Revenue
- 2697500
- Revenue Yoy
- 33.3%
- Total Assets
- 10106900
- Cash Position
- 616500
- Shares Outstanding
- 11928599
- Q2 Revenue
- 1470400
- Q2 Revenue Yoy
- 36.0%
- Gross Margin Q2
- 42.3%
- Genie Earnout Max
- 1500000
- Accumulated Deficit
- 37974000
- Prior Year Q2 Revenue
- 1081000
- Shareholders Equity
- 8074300
- Gross Margin Six Months
- 40.5%
- Investment Securities
- 3932000
- Genie Division Sale Price
- 9600000
- Genie Earnout Guaranteed
- 1140000
- Customer Concentration Q2
- two customers ~49% of revenue
- Benchtop Segment Q2 Revenue
- 1196200
- Prior Year Six Month Revenue
- 2023300
- Bioprocessing Segment Q2 Revenue
- 274200
- Deferred Tax Valuation Allowance
- 13484039
- Options Outstanding At June302026
- 3326518
- Warrant Shares Excluded From Dilution
- 7627350
- Benchtop Segment Q2 Gain From Operations
- 57500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.